Quantifying absolute neutralization titers against SARS-CoV-2 by a standardized virus neutralization assay allows for cross-cohort comparisons of COVID-19 sera

Kasopefoluwa Y. Oguntuyo[1#], Christian S. Stevens[#], Chuan-Tien Hung[1], Satoshi Ikegame[1], Joshua A. Acklin[1], Shreyas S. Kowdle[1], Jillian C. Carmichael[1], Hsin-Ping Chiu[1], Kristopher D. Azarm[1], Griffin D. Haas[1], Fatima Amanat[1], Jéromine Klingler[2,3], Ian Baine[4], Suzanne Arinsburg[4], Juan C. Bandres[2,3], Mohammed N.A. Siddiquey[5], Robert M. Schilke[5], Matthew D. Woolard[5], Hongbo Zhang[5], COVIDAR Argentina Consortium[6], Andrew J. Duty[1], Thomas A. Kraus[1], Thomas M. Moran[1], Domenico Tortorella[1], Jean K. Lim[1], Andrea V. Gamarnik[1*], Catarina E. Hioe[1,2,3], Susan Zolla-Pazner[1,2], Stanimir S. Ivanov[5], Jeremy P. Kamil[5], Florian Krammer[1], and Benhur Lee[1]

Affiliations:

1. Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029
2. Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029
3. James J. Peters VA Medical Center, Bronx, NY, 10468
4. Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, 10029
5. Department of Microbiology and Immunology, Louisiana State University Health Science Center Shreveport, Shreveport, LA 71103
6. COVIDAR Argentina Consortium*, Buenos Aires, Argentina

[#]These authors contributed equally to this work.

[*]COVIDAR Argentina Consortium:

Ojeda DS, Gonzales Lopez Ledesma MM, Costa Navarro GS, Pallarés HM, Sanchez LN, Perez

P, Ostrowski M, Villordo SM, Alvarez DE, Caramelo JJ, Carradori J, Yanovsky MJ, Gamarnik

AV

i.   Fundacion Instituto Leloir-CONICET, Buenos Aires, Argentina

ii.   Universidad Nacional de San Martin, Buenos Aires, Argentina

iii.   Laboratorio Lemos SRL, Buenos Aires, Argentina

iv.   INBIRS-CONICET, Facultad de Medicina, Universidad de Buenos Aires, Argentina

Author contributions:

KYO, CSS and BL conceived and designed the study. KYO, CSS, CTH, SI, JAA, SSK, JCC,

HPC, KDA, GDH, FA, JK, IB, SA, JCB, SSI, MNAS, RMS, MDW, HZ, and COVIDAR

Argentina Consortium collected data. GDH, JAD, TAK, TMM, DT, JKL, AVG, CEH, SZP, SSI,

JPK, and FK contributed valuable reagents, data and/or tools. KYO and CSS analyzed the data

and wrote the original drafts of the paper. BL reviewed the draft, supported data analysis, and

provided invaluable direction throughout the conceptualization and execution of the project. All

authors had the opportunity to review the manuscript prior to submission and SI, JCC, KDA, DT,

and JPK provided valuable feedback during the editing process.

Abstract

The global COVID-19 pandemic has mobilized efforts to develop vaccines and antibody-based therapeutics, including convalescent plasma therapy, that inhibit viral entry by inducing or transferring neutralizing antibodies (nAbs) against the SARS-CoV-2 spike glycoprotein (CoV2-S). However, rigorous efficacy testing requires extensive screening with live virus under onerous BSL3 conditions which limits high throughput screening of patient and vaccine sera. Myriad BSL-2 compatible surrogate virus neutralization assays (VNAs) have been developed to overcome this barrier. Yet, there is marked variability between VNAs and how their results are presented, making inter-group comparisons difficult. To address these limitations, we developed a standardized VNA using VSVΔG-based CoV-2-S pseudotyped particles (CoV2pp) that can be robustly produced at scale and generate accurate neutralizing titers within 18 hours post-infection. Our standardized CoV2pp VNA showed a strong positive correlation with CoV2-S ELISA and live virus neutralizations in confirmed convalescent patient sera. Three independent groups subsequently validated our standardized CoV2pp VNA (n>120). Our data show that absolute (abs) IC50, IC80, and IC90 values can be legitimately compared across diverse cohorts, highlight the substantial but consistent variability in neutralization potency across these cohorts, and support the use of absIC80 as a more meaningful metric for assessing the neutralization potency of vaccine or convalescent sera. Lastly, we used our CoV2pp in a screen to identify ultra-permissive 293T clones that stably express ACE2 or ACE2+TMPRSS2. When used in combination with our CoV2pp, we can now produce CoV2pp sufficient for 150,000 standardized VNA/week.

Importance

Vaccines and antibody-based therapeutics like convalescent plasma therapy are premised upon

inducing or transferring neutralizing antibodies that inhibit SARS-CoV-2 entry into cells. Virus

neutralization assays (VNAs) for measuring neutralizing antibody titers (NATs) is an essential

part of determining vaccine or therapeutic efficacy. However, such efficacy testing is limited by

the inherent dangers of working with the live virus, which requires specialized high-level

biocontainment facilities. We therefore developed a standardized replication-defective

pseudotyped particle system that mimics entry of live SARS-CoV-2. This tool allows for the safe

and efficient measurement of NATs, determination of other forms of entry inhibition, and

thorough investigation of virus entry mechanisms. Four independent labs across the globe

validated our standardized VNA using diverse cohorts. We argue that a standardized and scalable

assay is necessary for meaningful comparisons of the myriad of vaccines and antibody-based

therapeutics becoming available. Our data provide generalizable metrics for assessing their

efficacy.

Introduction

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is an enveloped, positive-sense, single-stranded RNA (+ssRNA) virus from the family *Coronaviridae*. SARS-CoV-2 is related to, but not derived from SARS-CoV, which we will refer to as SARS-CoV-1 for clarity. SARS-CoV-1 and SARS-CoV-2 belong to the genus *Betacoronavirus* and group together as sarbecoviruses, a subgenus that also contains numerous bat "SARS-like" CoVs.[1] SARS-CoV-1 caused a limited epidemic of SARS from 2002-2004, infecting ~8,000 people and killing 774.[2,3] SARS-CoV-1 was ultimately contained and has not reappeared. SARS-CoV-2 is the causative agent for coronavirus disease 2019 (COVID-19). The Chinese government first reported a cluster of 40 cases of atypical pneumonia (now known to be COVID-19) to the WHO on 30 Dec 2020. Since then, SARS-CoV-2 has erupted into a global pandemic, resulting in approximately 15 million cases and more than half a million deaths in less than 8 months.[4]

The emergence and spread of SARS-CoV-2 has required a global response to mitigate the fallout from the pandemic. As a result, the highest priorities for governments around the world are prevention, treatment, and monitoring of infection and immunity.[5] Understanding and monitoring immune responses to SARS-CoV-2 is critical for development of antibody-based therapeutics and vaccines. Both are challenging to study at the necessary scale due to the inherent danger of working with live virus and limited access to high level biosafety containment facilities (i.e. BSL3). However, the development of pseudotyped viral particles capable of recapitulating SARS-CoV-2 entry—without the dangers or limitations of working with live virus—addresses these concerns. Many such pseudotype virus (PsV) systems based on lentivirus

or vesicular stomatitis virus backbones have been published.[6–9] These PsV systems have been

used to understand and assess humoral immunity in acute and recovered COVID-19 patients, and

to screen for therapeutic entry inhibitors, such as small molecules, monoclonal antibodies, or

convalescent sera. Most importantly, such a surrogate BSL2 virus neutralization assay (VNA) is

needed to screen for vaccine induced responses, in domestic animals and humans, as the world

rushes to develop candidate vaccines against SARS-CoV2.

As of this writing, at least five SARS-CoV-2 vaccine developers have reported Phase I/II results

involving over 1700 participants.[10–15] While each group claims promising results, it is difficult to

compare vaccine induced immune responses between the various vaccine platforms. This is not

only due a lack of a standardized reporting but also due to a lack of standardized assays for

reporting virus neutralization titers. Furthermore, at least 16 studies have reported 350 patients

receiving convalescent plasma therapy for COVID-19. Across all 16 plasma studies, some

groups establish enzyme-linked immunosorbent assays (ELISA) or live virus neutralization

thresholds to screen donor plasma , while others do not report binding or neutralization data.[16–33]

Notably, none of these studies report using a PsV VNA to screen donor plasma. These

discrepancies in screening methods/metrics limit the ability to compare across groups and make

it difficult to draw conclusions about the quality/potency of antibody transferred to the

recipient.[32,33]

A standardized virus neutralization assay (VNA) that provides robust, high-throughput results

(>100,000 infections/week), is easily "kit-able", and generates absolute virus neutralization titers

(VNT), would allow for meaningful comparisons across different labs. In addition to helping

down-select the myriad vaccine candidates, use of a standardized VNA to report VNT in

absolute units can crowd-source the immense effort being expended by multiple labs across the

globe to better understand the basis of the marked variation in VNT seen in COVID-19

recovered patients.[34,35]

The SARS-CoV-2 spike glycoprotein (S) is embedded in the viral envelope and facilitates both

receptor recognition and membrane fusion. SARS-CoV-2-S is 1273 amino acids in length and,

like other coronaviruses, is a trimeric class I fusion protein.[36] The S glycoprotein contains two

subunits, the N-terminal, S1 subunit and the C-terminal, S2 subunit. The S1 subunit contains the

receptor-binding domain (RBD), which is responsible for host receptor binding. The S2 subunit

contains the transmembrane domain, cytoplasmic tails, and machinery necessary for fusion,

notably the fusion peptide and heptad repeats.[37,38] Angiotensin-converting enzyme 2 (ACE2), a

cell surface enzyme in a variety of tissues, facilitates binding and entry of SARS-CoV-2.[39–41]

However, ACE2 alone is not sufficient for efficient entry into cells. While entry depends on the

S1 subunit binding ACE2, entry is further enhanced by proteolytic cleavage between the S1/S2

and S2' subunits. For both SARS-CoV-1 and SARS-CoV-2, this cleavage-mediated activation of

S-mediated entry is supported by the expression of cell-associated proteases, like cathepsins or

transmembrane serine protease 2 (TMPRSS2), or the addition of exogenous proteases that mimic

the various trypsin-like proteases present in the extracellular lung milieu.[39,42–51] These proteases

facilitate entry at the cell surface or via an endosomal route in a cell-type dependent manner.

Extracellular proteases are thought to play a pathophysiogical role in the lung tissue damage

caused by unabated MERS-CoV, SARS-CoV-1, and likely SARS-CoV-2 replication.[49,50] Thus,

in order to represent SARS-CoV-2 cell entry faithfully, a viral neutralization assay (VNA) must

be sensitive not only to ACE2 binding but also to the proteolytic activation of spike.

In addition to its role in receptor binding and entry, S is the primary surface glycoprotein and is

the major target of the neutralizing antibody response.[52–56] Patients infected with SARS-CoV-2

typically seroconvert within two weeks of symptom onset, with about half developing antibodies

within 7 days.[57–59] Antibody titers appear to be durable at greater than 40 days post infection,[58]

but in the case of SARS-CoV-1, reductions in IgG positive titers begin around 4-5 months post

infection and show a significant drop by 36 months.[60] Although there are reports of SARS-CoV-

2 infected individuals testing positive by RT-PCR weeks after being confirmed as recovered by

two consecutive negative tests, these are more likely the result of false negatives than of

reinfection.[61,62] Multiple groups have shown that fully recovered rhesus macaques previously

infected with SARS-CoV-2 are refractory to reinfection, at least within four weeks of the

primary challenge.[63,64] However, a better understanding of the durability and efficacy of the

neutralizing antibody response in patients previously infected with SARS-CoV-2 is of paramount

importance. Not only do IgG titers wane in the case of SARS-CoV-1, but reinfection is possible

in other endemic human coronaviruses (HCoVs) such as 229E, NL63, and OC43 in as little as a

year.[65–67] Whether the waning of neutralizing SARS-CoV-2 antibodies impacts susceptibility to

re-infection is an urgent question that needs to be answered by longitudinal follow-up studies.[68–

71]

Humoral immune responses to the SARS-CoV-2 S protein are typically evaluated by ELISAs

and its many variants (CLIA, LFA, etc.). These serological binding assays rightfully play a

central role in determining patient antibody responses and can complement diagnostics and sero-

epidemiological studies, especially when combined with antibody subclass determination (IgM,

IgA and IgG).[72–74] Nonetheless, as many antibodies generated to the spike protein bind but do not

block virus entry,[75–78] ELISA-based assays that detect titers of spike-binding antibodies cannot

always correlate perfectly with neutralizing antibody titers as measured by plaque reduction

neutralization or microneutralization tests.[74,79–82] Even a cleverly designed competitive ELISA

set up to detect antibodies that block the binding of RBD to ACE2[76,83] cannot capture the

universe of neutralizing antibodies targeted to a conformationally dynamic trimeric spike on a

virion.[84,85] The gold standard for detecting antiviral antibodies remains the virus neutralizing

assay. Assays that faithfully recapitulate entry of SARS-CoV-2 while maximizing safety, speed,

and scalability will be vital in the coming months and years. They will enable monitoring of

patient neutralizing antibody response, efficacy of vaccines and entry inhibitors, and the

screening of convalescent plasma from COVID-19 recovered patients.[57,86]

In order to meet this need while maximizing safety, speed, and scalability, we generated a

SARS-CoV-2 pseudotyped viral particle (CoV2pp) by using vesicular stomatitis virus bearing

the *Renilla* luciferase gene in place of its G glycoprotein (VSVΔG-rLuc). This approach has been

used safely by our group and others to study viruses that would otherwise require significant

biosafety constraints, including Ebola virus, Nipah virus, and, most recently, SARS-CoV-2.[6,8,87–

90] Here, we present a detailed protocol for the production of CoV2pp, characterize the

contributions of stable expression of ACE2 as well as endogenous or exogenous proteases on

entry, and standardize the production and performance characteristics of these CoV2pp for use in

a robust high throughput VNA. We have sent out our standardized CoV2pp as ready-to-use "out

of the box" VNAs, $\geq$1000 infections/request, to multiple labs across three continents. We show

here the validation of our CoV2pp in a standardized VNA by four independent groups spread

across two continents using sera samples from geographically distinct and ethnically diverse

cohorts. Lastly, we utilized our standardized CoV2pp and VSV-Gpp in a screen to identify two

ultra-permissive 293T cell clones that stably express either ACE2 alone or ACE2+TMPRSS2.

These isogenic cell lines support either the late (293T-ACE2) or early (293T-ACE2/TMPRSS2)

entry pathways that SARS-CoV-2 uses.[40,45,50,91] These ultra-permissive 293T clones allow for

use of unpurified virus supernatant from our standard virus production batch, which can now

provide for ~150,000 infections per week (96-well format) with no further scale-up. In sum, we

have generated a standardized, scalable, high-throughput BSL2-compatible CoV2pp VNA that

can provide robust metrics (absIC50, absIC80, absIC90) for meaningful comparisons between

labs.

Results:

Production of VSVΔG-rLuc bearing SARS-CoV-2 spike glycoprotein

Our initial objective was to produce SARS-CoV-2 PsV sufficient for ≥10,000 infections/week at

~1:100 signal:noise ratio when performed in a 96-well format. We settled on a VSV-based rather

than a lentiviral PsV system as lentiviruses are intrinsically limited by their replication kinetics

and particle production rate (10^4-10^6/ml for lentiviruses versus 10^7-10^9/ml for VSV without

concentration). We optimized the production of our VSVΔG-rLuc pseudotyped viral particles

(pp) bearing the SARS-CoV-2 spike glycoprotein as diagramed in Figure 1A. A detailed

production protocol is given in Supplementary Methods. Notably, this protocol involves

infecting producer cells at a low multiplicity of infection (MOI) of stock VSVΔG-G*, incubating

producer cells with an anti-VSV-G monoclonal antibody and generating the pseudotyped

particles in Opti-MEM media. The first two measures effectively eliminated the background

signal from residual VSV-G while the last measure allowed for more cleavage of SARS-CoV-

2pp in producer cells (Supplemental Figure 1). While others have shown that truncating the

cytoplasmic tail (CT) of SARS-CoV-2-S is typically required for greater functional incorporation

into heterologous viral cores,[7,9,92,93] we chose to optimize pseudotyping with full-length SARS-

CoV-2 spike. CT truncations in many other class I viral fusion proteins, including other ACE2-

using coronaviruses (HCoV-NL63 and SARS-CoV-1) can affect ectodomain conformation and

function.[94–103] Until such time that we gain a fuller understanding of SARS-CoV-2 entry, we felt

it was necessary to have a surrogate assay that reflects the biology of the full-length virus spike.

Following the protocol detailed in Supplementary Methods, we produced BALDpp, NiV-RBPpp,

CoV2pp, and VSV-Gpp using the VSVΔG-rLuc reporter backbone and titered them on Vero-

CCL81 cells (Fig. 1B). High background problems have resulted in low signal:noise ratios when

using VSV-based PsV, especially for viral envelope proteins that do not mediate efficient entry.

Here we used two different negative controls, BALDpp and NiV-RBP, to show that we resolved

the background issue. BALDpp lacks any surface glycoprotein while NiV-RBPpp incorporates

the NiV receptor binding protein (RBP), which binds to the broadly expressed ephrin-B2 with

sub-nanomolar affinity.[88,104] However, the NiV fusion (F) glycoprotein necessary for viral entry

is absent. NiV-RBPpp without NiV-F should not fuse and effectively serves as a stricter and

complementary negative control. Under the conditions shown, neither BALDpp or NiV-RBPpp

gives any background even at the highest concentration of virus particles used.

These constructs were used to infect Vero-CCL81 cells and, as expected, we observe an average

of <500 RLUs of entry with our BALDpp and NiV-RBPpp negative controls. These levels of

entry were comparable to the "cells only" signal, providing confidence in any infection signals

10-fold over background. Undiluted CoV2pp entry resulted in luciferase values of over 50,000

RLUs; greater than 100-fold over background BALDpp signals (Fig. 1B). VSV-Gpp gave

several logs higher infectivity as expected. Western blots of the producer cells demonstrated

effective expression of cleaved, SARS-CoV-2 spike glycoproteins (Fig. 1C, left panel). Cleaved

CoV-2 spike products (S1, S2, and S2') all appear to be incorporated into the VSVΔG

pseudotyped particles (Fig. 1C, right panel). To ensure that entry of CoV2pp is SARS-CoV-2

spike-mediated, we show that the homologous soluble spike receptor binding domain (sRBD)

competitively inhibits our CoV2pp (Fig. 1D).

CoV2pp entry is enhanced by trypsin treatment and spinoculation

Next, we sought to enhance the relative signal of our CoV2pp infections, which will effectively

increase the number of infections we can provide or perform per batch of CoV2pp. Trypsin

treatment is reported to enhance SARS-CoV-1 and SARS-CoV-2 entry.[39,45] Thus, we treated

CoV2pp stocks with the indicated range of trypsin concentrations for 15 min at room

temperature (Fig. 2A). In order to mitigate the effects of trypsin-dependent cytotoxicity, we

added 625µg/mL of soybean trypsin inhibitor (SBTI) to all samples before titrating the trypsin-

treated CoV2pp onto Vero-CCL81 cells. CoV2pp treated with the highest concentration of

trypsin (625µg/mL) resulted in ~100-fold enhancement of entry (Fig. 2A), but this trypsin-

dependent enhancement was only apparent when comparing entry of undiluted trypsin-treated

CoV2pp. We observed a greater than 50-fold reduction in entry (RLUs) after a 10-fold serial

dilution, which nullified any entry enhancement effects of trypsin. Indeed, the role of trypsin in

enhancing SARS-CoV-2 entry has not been fully determined. Trypsin may be acting to prime

CoV2pp to facilitate better entry upon spike-receptor interactions and/or assist to proteolytically

activate spike protein at or after receptor binding.[50] We hypothesized that the remaining

uninhibited trypsin-dependent effect, which must be present at the highest trypsin concentration,

was inadvertently neutralized by diluting the trypsin-treated CoV2pp in Dulbecco's modified

Eagle Medium (DMEM) +10% fetal bovine serum (FBS), which is the standard infection media

for titrating CoV2pp. To test this hypothesis, we diluted CoV2pp and trypsin-treated CoV2pp

1:10 in three different media conditions before infecting Vero-CCL81 cells. For trypsin-treated

CoV2pp, dilution in DMEM alone (serum free media, SFM) produced the highest signal:noise

ratio, almost 1000-fold over BALDpp (Fig. 2B). As a result, we chose CoV2pp treated with

625µg/mL of TPCK-treated trypsin, then 625µg/mL of SBTI, diluted in SFM as our standard

treatment condition. Furthermore, spinoculation at 1,250rpm for 1hr enhanced entry 3-5 fold

(compare signal:noise in Fig. 2B to Supplemental Fig. 2).

Our above hypothesis suggests that the uninhibited trypsin-dependent enhancing effect was

acting at the point of infection when CoV2pp is interacting with the host cell receptor. To

investigate further, we spiked in additional SBTI onto cells at the time of infection using

particles produced under the standard treatment condition as above. We found that additional

SBTI (≥25µg/mL) added directly to cells at the point of infection was able to inhibit trypsin-

dependent entry enhancement (Fig. 2C). The data suggest that some trypsin was not inhibited by

the first 625µg/mL of SBTI and enough remained to enhance entry at the point of infection (Fig.

2D).

Entry of CoV2pp is independently enhanced by stable expression of ACE2 and TMPRSS2

in cells already permissive for SARS-CoV-2 entry and replication

To further characterize the determinants of CoV2pp entry, we generated Vero-CCL81 cell lines

stably expressing human ACE2 or human TMPRSS2. Vero-CCL81 cells are already highly

permissive for SARS-CoV-2 entry and replication. We infected the indicated cells with CoV2pp

or trypsin-treated CoV2pp diluted in serum-free media (standard treatment) and observed

enhanced entry in both stable cell lines (Fig. 3A). However, the entry enhancement of trypsin-

treated CoV2pp in Vero-CCL81+TMPRSS2 overexpressing cells was subdued relative to

untreated CoV2pp. This suggests that the presence of exogenous trypsin during CoV2pp entry

can substitute, in part, for the role played by cell surface TMPRSS2, an endogenous protease

known to facilitate entry into physiological relevant cell types *in vivo*.[105] Fig. 3B shows that the

relationship between ACE2 and TMPRSS2 expression—with regard to their effect on enhancing

SARS-CoV-2 spike mediated entry—is not straightforward. As ACE2 itself is a substrate for

TMPRSS2, the right stoichiometry of receptor/protease expression appears to be the main driver

of entry efficiency rather than the absolute expression of one or the other. This issue will be

further examined in the last section.

Standardizing the parameters that impact CoV2pp-based virus neutralization assay

Having established that exogeneous trypsin can serve as a physiologically relevant substitute for

endogenous proteases known to enhance entry of CoV2pp, such as TMPRSS2, we sought to

characterize the parameters that might affect the performance our CoV2pp VNA. Conditions

tested included heat-inactivation of sera and the infection media used to dilute human sera

samples. We used representative spike ELISA positive or negative sera to serve as positive and

negative controls, respectively. When first diluted in SFM, we observed that negative sera can

have alarming amounts of neutralizing activity that appeared specific for CoV2pp as the same

sera did not neutralize VSV-Gpp entry (compare Supplemental Figures 3A with 3B, right panel).

This CoV2pp serum neutralizing factor is somewhat reduced but not completely diminished by

heat inactivation for 1hr at 56ºC. Notably, the effect of this neutralizing factor from negative sera

was preempted by diluting the trypsin treated CoV2pp in DMEM containing 10% FBS

(Supplemental Fig. 3B). Importantly, recombinant sRBD neutralization was not affected by the

dilution of CoV2pp in Serum Free Media or DMEM+10% FBS (Supplemental Fig. 3C). The

nature of this factor that appears to inhibit spike-mediated entry is the subject of a concurrent

manuscript in submission (see Discussion). Regardless, for standardizing our CoV2pp-based

VNA, all subsequent patient sera were heat inactivated for at least 30 mins prior to use and

serially diluted in DMEM + 10% FBS, which also served as our infection media. Despite our

data from Fig. 2 implicating a trypsin-inhibitor-like activity in FBS, the marked inhibition of

CoV2pp entry by seronegative human sera is a greater limiting factor that prevents the robust

determination of true SARS-CoV-2 Nab titers. To achieve the same signal:noise ratio while

performing our VNA in the presence of 10% FBS, we increased the concentration of CoV2pp

used per infection.

Performance characteristics of our standardized CoV2pp virus neutralization assay

An initial set of sera for validation of CoV2pp VNA was generously provided by Dr. Florian

Krammer. These sera were screened according to a previously described two-stage ELISA

protocol in which 1:50 dilutions of patient sera were first screened for reactivity against sRBD.

Subsequently, the presumptive RBD-positive patient sera were used to assess reactivity to the

trimer stabilized ectodomain of spike at five different dilutions (1:80, 160, 320, 960, and

2880).[73,106] These samples were used for neutralization studies with CoV2pp (Fig. 4A and 4B).

From the 36 patient sera tested, 6 were found to be negative for SARS-CoV-2 spike binding in

the ELISA described above. All of those 6 sera samples also showed no neutralization of

CoV2pp. The remaining 30 spike positive sera had 50% neutralizing titers that span 2 orders of

magnitude (Fig. 4B, 160 – 10,240). For a more quantitative assessment, we determined the total

IgG and IgM spike binding activity (ELISA AUC as described in Methods) of a representative

subset of fifteen sera samples and compared them with their reciprocal absIC50 and absIC80

values calculated from the CoV2pp neutralization curves (Fig.4A) as described in Methods.

Spike binding antibodies (IgG+IgM ELISA AUC) demonstrated a significant, positive

correlation with neutralizing antibody (nAb) titers (reciprocal absIC50 and absIC80) as

determined by our CoV2pp VNA (Fig. 4C, green circles). Moreover, these Nab titers against

CoV2pp also correlated well with live virus microneutralization titers (MN absIC50, MN

absIC80) (Fig. 4C, brown triangles). Full neutralization curves for the MN titers are shown in

Supplemental Figure 4. AbsIC80 appeared to be a more stringent measure of nAb activity, as

some sera that have respectable MN absIC50 titers never achieve an absIC80 (Fig. 4C, bottom

graph, brown triangles on the x-axis). In this respect, the CoV2pp VNA has a larger dynamic

range and was more sensitive in its ability to sort out sera samples that can reach their respective

absIC80 values. Notably, we find that sera samples with potent absIC50 titers do not always

display potent absIC80 values (Fig. 4D).

Independent validation of our CoV2pp VNA with geographically distinct and ethnically

diverse COVID-19 patient cohorts

To assess the robustness of our standardized CoV2pp VNA, we produced and distributed the

CoV2pp to many labs who have requested our assay for use in various screens for nAbs. Here,

we analyze and present the raw virus neutralization data provided to us by three independent

groups at the Icahn School of Medicine at Mount Sinai (ISMMS-2), Louisiana State University

Health Sciences Center Shreveport (LSUHS), and Argentina (COVIDAR). In sera or plasma

neutralization studies, these groups also observe similar absIC50, absIC80, and absIC90

distributions. The LSUHS and ISMMS-2 cohorts represent data from 25 and 28 seropositive as

well as 10 and 11 seronegative samples, respectively, while the COVIDAR consortium assessed

neutralization from an initial set of 13 seropositive patient samples. For clarity, analysis of their

neutralization curves is presented as heatmaps in Fig. 5A similar to what was shown in Fig. 4B.

Full neutralization curves for each cohort are shown in Supplemental Figure 5.

The seronegative control samples from all groups revealed no CoV2pp neutralization. Rare, but

notable, seropositive samples from LSUHS also showed no neutralization (Fig. 5A, LSUHS).

ISMMS-2 performed their analysis on confirmed convalescent plasma donors.[32] While all donors

had detectable nAb titers, their titers were highly variable and ranged across 2-3 logs. AbsIC80s

were calculated for all samples shown and we observed a moderate, but significant, positive

correlation between various spike ELISA metrics and absIC80 (Fig. 5B).

Aggregated reciprocal absIC80 from all three external labs as well as our own are shown in Fig.

5C. Notably, we observe a Gaussian distribution of reciprocal absIC80s from all groups (n=89).

The descriptive statistics from this aggregated data set reveals reciprocal absIC80 25th percentile

of 68.5, median of 170.8, and 75th percentile of 343.4. Descriptive statistics for reciprocal

absIC50 and absIC90 were also calculated and are reported in Supplemental Table 1. Using the

absIC80 descriptive statistics above and the ELISA endpoint titers from our initial 36 sera

samples, we observe that 0% of the samples displaying an ELISA endpoint titer of 320 have an

absIC50 greater than the median IC50. Perhaps not surprisingly, over 90% of samples with

ELISA endpoints of 2880 have IC50s at or beyond the 75th percentile (Table 1, represented

graphically in Supplemental Figure 6). Although absIC80 also generally follows this trend, we

once again note differences in the ranked order of absIC50 and absIC80 values calculated for all

sera samples (Supplemental Figure 7). This difference is more pronounced when comparing the

absIC50 and absIC90 graphs further highlighting the need for a neutralization assay with a broad

dynamic range. Additionally, the samples from each of the 4 groups show no statistical

difference when absIC50, 80, or 90 calculations are compared (Supplemental Figure 8).

Altogether, these data support the robustness of our CoV2pp VNA and suggest that absIC80 is a

more stringent and meaningful measure of Nab titers.

Ultra-permissive 293T-ACE2 and 293T-ACE/TMPRSS2 clones allow for use of CoV2pp in

VNA at scale

Although our standardized VNA appears robust, the requirement for exogenous trypsin and

spinoculation to achieve the optimal signal:noise limits the scalability of our VNA. Therefore,

we used our untreated CoV2pp to screen for ultrapermissive cell lines that would allow for our

CoV2pp VNA to be performed with dilutions of virus supernatant without any trypsin treatment,

virus purification, or spinoculation.

We generated three different 293T cell lines stably expressing ACE2 and/or TMPRSS2 via

lentiviral transduction. We then infected these cells with CoV2pp. Increased expression of

TMPRSS2 alone (293T-TMPRSS2) did not significantly improve entry (Fig. 6A), likely due to

the low to undetectable ACE2 expression levels (Fig. 6B, lanes 1 and 3). However, expression of

ACE2 significantly increased the entry of CoV2pp, which was further increased in 293T-

ACE2+TMPRSS2 cells, suggesting the synergistic activity of TMPRSS2 and ACE2 (Fig. 6A).

Western blot analysis confirmed the increased expression of ACE2 in the singly and doubly

transduced 293T cells (Fig. 6B). Additionally, increased expression of both ACE2 and

TMPRSS2 was confirmed by qPCR (Supplemental Fig. 9B). Interestingly, ACE2 expression

appeared to be decreased by >50% in 293T-ACE2+TMPRSS2 cells relative to 293T-ACE2 cells.

These observations highlight the complex roles that receptor binding and protease activation play

in SARS-CoV-2 entry, especially since ACE2 is a known substrate for TMPRSS2,[107] and

TMPRSS2 is also known to undergo autocatalytic cleavage.[108]

Given how TMPRSS2 can enhance ACE2 dependent virus entry in a non-linear fashion, we used

BALDpp, CoV2pp, and VSV-Gpp to screen 19 single cell clones derived from 293T-ACE2 or

293T-ACE2+TMPRSS2 or Vero-ACE2 bulk transduced cells. The latter (Fig. 3) served as an

additional control in a naturally permissive cell line for SARS-CoV-2 entry and replication. All

three bulk transduced cell lines resulted in significant increases in entry of CoV2pp relative to

the parental 293T and Vero CCL81 cells (Supplemental Fig. 9 and Fig. 6C). However, only a

subset of the single cell clones performed better than bulk transduced cells. This is especially

notable in single cell clones derived from 293T-ACE2+TMPRSS2 parentals, where only two of

eight single cell clones show greater entry than the bulk transduced cells (Fig. 6C). One

particular clone, F8-2 (Fig. 6C) showed a nearly ten-fold increase in CoV2pp entry relative to the

bulk transduced cells. Using F8-2 to titer untreated CoV2pp without spinoculation, we observed

a dramatic increase in signal:noise relative to Vero-CCL81 WT cells and even the most

permissive 293T-ACE2 clone 5-7 (Supplemental Figure 10) such that RLU signals were

consistently 100-200 fold over BALDpp even at 1:50 dilution. TMPRSS2 was determined to be

the main driver of this entry enhancement in the F8-2 cells as treatment with Nafamostat, a

serine protease inhibitor, potently inhibited entry. However, this entry inhibition plateaued at

90% of maximal infection and the remaining 10% is nearly equivalent to the raw RLU values

seen with bulk 293Ts stably expressing ACE2 alone (Fig. 6D and Supplemental Figure 9),

suggesting a TMPRSS2-independent mechanism of entry. Entry into 293T-ACE2 cells was not

inhibited by Nafamostat, once again highlighting that CoV2pp can enter by both the early and

late entry pathways that have differential protease requirements.

Diverse cell lines maintain similar kinetics in CoV2pp viral neutralization assays:

We identified sera samples from 15 patients shown in Fig. 4A and tiered them into three groups:

negative for CoV2pp neutralization (negative), weakly positive for CoV2pp neutralization (low

positive), or strongly positive for CoV2pp neutralization (high positive) (Fig. 7A). We then

pooled equal volumes of each set of samples and performed CoV2pp neutralization assays on

Vero-CCL81 WT, 293T-ACE2 clone 5-7, 293T-ACE2+TMPRSS2 bulk transduced, and the

293T-ACE2+TMPRSS2 clone F8-2. We demonstrated that even in the case of varying levels of

ACE2 and TMPRSS2 expression, CoV2pp neutralization assays show consistent patterns of

neutralization, exhibiting the robust nature of the assay in tandem with its sensitivity in detecting

relative differences in neutralizing titer (Fig. 7B). Patterns of neutralization as well as the

calculated absIC50 and absIC80 reveal a large dynamic range between low and high neutralizing

patient sera across cell lines (Fig. 7B).

Discussion

Here, we present detailed and optimized protocols for producing VSVΔG pseudotyped viral

particles bearing SARS-CoV-2 spike protein. These CoV2pp recapitulate the SARS-CoV-2 entry

requirement for ACE2 expression on the host cell and enhanced infectivity in the presence of

activating proteases such as trypsin and/or TMPRSS2 in both 293T and Vero cells. Evidence

from our original standard condition suggested that only a minor fraction of the trypsin added

was required, and this trypsin acted at the level of receptor binding on the host cell (Fig. 2C and

D). Due to the observed effect of trypsin at the point of infection, we hypothesize that interaction

with a cellular factor, likely ACE2, induces conformational changes necessary for further

protease-mediated activation, likely at the S2' cleavage site, of SARS-CoV-2 spike. Moreover, in

a competitive inhibition assay, entry by the trypsin-treated CoV2pp was successfully inhibited by

sRBD. This faithful recapitulation of the entry processes previously described for SARS-CoV-1

and SARS-CoV-2 suggests that the trypsin treated CoV2pp represent a biologically relevant

system for identifying cells that support SARS-CoV-2 entry and for screening for entry

inhibitors, especially neutralizing antibodies or patient sera.

Prior to the use of trypsin-treated CoV2pp for neutralization experiments, we assessed how heat

inactivation of sera and different cell media affect neutralization. Here, we report detectable

neutralization by negative patient sera, which was previously reported in mouse and human sera

by Nie et al.[8] However, it is unclear whether the sera used by Nie et al was heat inactivated. Our

observations also raise questions concerning the role the previously mentioned heat-labile serum

factor might play *in vivo*. We have shown that the CoV2pp VNA displays high sensitivity to the

inhibition of protease-mediated entry enhancement by human serum, FBS, SBTI, and even

Nafamostat when the protease in question is TMPRSS2. The inhibitory potential of human serum

implies a potential role serum factors could play in SARS-CoV-2 pathogenicity, tissue

restriction, and systemic spread in previously SARS-CoV-2 naïve patients (manuscript in

submission). These findings led to the establishment of heat inactivation of sera and use of

DMEM+10% FBS as conditions for trypsin-treated CoV2pp neutralization experiments. When

used for viral neutralization assays with patient sera, the absIC50/absIC80 against CoV2pp

correlated strongly with full-length spike ELISAs and live virus microneutralization titers.

Moreover, we have produced several batches of our CoV2pp and shipped them (along with

Vero-CCL81 cells) to many other groups as an "out-of-the-box" neutralization assay. The first

three groups to receive these particles, and who have volunteered their data, have successfully

screened patient sera with our assay and observed moderate but significant correlations to spike

ELISAs.

While ELISAs provide valuable information about epitopes recognized by individual samples

and antibody quantities, functional studies allow for more in-depth analyses of neutralization

potential. Notably, RBD-binding antibodies, particularly those that can inhibit ACE2 binding,

have received a large amount of attention. However, recent studies identifying non-RBD

binding—yet still neutralizing—antibodies, lend insight into novel neutralization mechanisms

and further highlight the importance of functional neutralization assays.[84,85] Moreover, our

standardized CoV2pp VNA has a large dynamic range that can generate robust neutralization

curves, which allows for the calculations of more stringent metrics such as absIC50/absIC80.

AbsIC50/absIC80 give a more meaningful description of the neutralization potential of a given

serum sample as many patient sera (and potentially vaccine sera) may not even achieve an

absIC80. Reporting such standardized metrics will allow more meaningful comparisons of

vaccine elicited humoral responses, as well as the neutralization potential of convalescent sera,

especially when the latter is used for convalescent plasma therapy. This is of particular

importance given the widely variable ratios of spike ELISA binding values and neutralizing

antibody titers in comparisons of patients infected by SARS-CoV-2 and patients receiving

vaccines for SARS-CoV-2.[13]

Early reports of convalescent sera therapies show a tolerable safety profile and modest benefits

from this therapeutic approach.[17,20,29,31–33,109] However, many of these trials only consider ELISA

neutralization titers and utilize extremely variable ELISA endpoint titers from not

reported/available to ranging from 1:40 to >1:1350. Interestingly, one pre-peer reviewed study

incorporated functional neutralization studies by utilizing trypsin-treated live virus to screen for

sera with >1:80 microneutralization titers on Vero E6 cells.[33] Given the wide variance in ELISA

titers as well as in virus neutralization titers, we believe convalescent plasma therapy will be

enhanced if patient sera are functionally screened and limited to only those displaying potent

neutralization titers. This will have the benefit of only transfusing patients with convalescent sera

that have a strong likelihood of substantial *in vivo* inhibitory potential, which is of particular

importance given the volumes transfused relative to a patient's total blood volume. Given our

results, a reasonable threshold might be a VNA-derived reciprocal absIC80 of ≥343.3 (i.e. ≥75th

percentile).

Lastly, we utilize the CoV2pp system to screen 19 single cell clones and identify two single cell

clones of interest. These clones (293T-ACE2 clone 5-7 and 293T-ACE2+TMPRSS2 clone F8-2)

both support effective viral entry in the absence of trypsin and spinoculation and can be used for

scaling up viral neutralization assays. The ultra-permissive 293T-ACE2+TMPRSS2 F8-2 clone

in particular can support the use of a standardized VNA at the scale needed for screening entry

inhibitors, vaccine samples, donor plasma, etc. Our standardized CoV2pp production lot from a

single lab at 30x 10-cm dishes was sufficient for ~12,000 infections/week when performed in a

96-well format. The trypsin-treated CoV2pp (diluted 1:4) gives 100:1 signal:noise ratio when

performed in a 100 μl infection volume on Vero-CCL81 cells with spinoculation. Using the

ultra-permissive F8-2 clone, a 1:50 dilution gives similar signal:noise without any trypsin

treatment or spinoculation. Thus, our weekly production lot becomes sufficient now for

~150,000 infections/week, which is enough for generating full neutralization curves for ~4,600

to ~6,200 samples (assuming an 8-point dilution series performed in quadruplicates or triplicates,

respectively).

Several recently described systems including VSV encoding the SARS-CoV-2 spike gene[9,110]

and lentiviruses pseudotyped to bear the spike protein,[111] are capable of serving as surrogate

assays for assessing viral neutralization by patient sera or monoclonal antibodies. The replication

competent VSV system is attractive but still relies on a truncated spike. We have not been able to

rescue one with the full-length tail, even in our F8-2 clone although we could rescue multiple

VSVs bearing various betacoronavirus spikes (all with truncated tails). Nonetheless, our

standardized CoV2pp based on the VSVΔG system presents many advantages including safety,

ease and speed-of-use, identity to full-length SARS-CoV-2 spike, versatility for studying spike

mutants, and a large dynamic range. First, the viral genome used in this system lacks a viral

glycoprotein, which limits the virus to single-cycle replication and mitigates concerns about viral

spread. Next, because of the efficient replication of VSV, this system can be used to further

interrogate SARS-CoV-2 entry in primary cells and allows for the detection of Renilla luciferase

(or the desired reporter gene) within 12-18 hours post infection. Additionally, the VSVΔG

system presented here represents viral entry in the absence of mutations or truncations for

enhanced fusogenicity and/or entry dynamics. Lastly, since a viral glycoprotein must be provided

in trans for every production, this system is not susceptible to mutations over several passages

and is not dependent on repeated, arduous rescue attempts for the study of naturally occurring

spike mutants or chimeric spike glycoproteins. These studies may prove beneficial as we

consider natural occurring spike mutations—described on platforms such as GISAID—and strive

to understand their influence on viral entry kinetics or the influence on escape from antibody

neutralization.

In sum, we present detailed and optimized protocols for the production of a BSL-2 -safe

VSVΔG-rLuc pseudoparticle and use it to interrogate viral entry. More importantly, we present

several resources that we believe will be invaluable during this global pandemic. This includes

cell lines (particularly 293T-ACE2+TMPRSS2 and Vero-CCL81-TMPRSS2 cells), and CoV2pp

that are ready to use "out-of-the-box" for mechanistic studies of viral entry or to screen inhibitors

of viral entry. Our findings, resources, and proposed guidelines have implications for

standardizing viral neutralization assays, with particular importance for screening therapeutic

monoclonal antibodies, vaccine efficacy, and convalescent sera.

Materials and Methods:

Plasmids

▢   SARS-CoV-2 spike is in a pCAGG backbone and expresses the codon optimized Wuhan-

Hu-1 isolate (NCBI ref. seq. NC_045512.2).

▢   SARS-CoV-2 sRBD (NCBI GenBank MT380724.1 from Krammer lab) is in a pCAGG

backbone and expresses the codon optimized sequence from the Wuhan-Hu-1 isolate.

sRBD-His used for neutralization studies was generated from this construct.

▢   VSV-G is in a pCAGG backbone and expresses wild type Indiana strain VSV-G

(Genbank: ACK77583.1).

▢   ACE2 packaging construct (GeneCopoeia, cat no EX-U1285-Lv105) uses a CMV

promoter to express TMPRSS2 and bears a puromycin selection marker in the integrating

cassette.

▢   TMPRSS2 packaging construct (GeneCopoeia, cat no EX-Z7591-Lv197) uses a CMV

promoter to express TMPRSS2 and bears a blasticidin selection marker in the integrating

cassette.

▢   psPAX2 2nd generation lentiviral packaging plasmid (Addgene #12259) expresses HIV-1

Gag, Pol, and Pro proteins.

▢   NiV-RBP is in a pCAGG backbone and expresses the HA-tagged codon optimized NiV

receptor binding protein.

All plasmids listed here are ampicillin resistant. These constructs were transformed into stellar

competent cells, grown in bacterial growth media containing carbenicillin, prepared using

Invitrogen's midiprep kit, and sequence verified prior to use for experiments.

Maintenance and generation of cell lines

Vero-CCL81 and 293T cells were cultured in DMEM with 10% heat inactivated FBS at 37ºC

with 5% CO_2. VSV-G pseudotyped lentiviruses packaging ACE2 or TMPRSS2 expression

constructs were generated by using Bio-T (Bioland; B01-01) to transfect 293T cells with the

second-generation lentiviral packaging plasmid (Addgene; 12259), pCAGG-VSV-G, and the

desired expression construct (i.e. ACE2 or TMPRSS2). The media was changed the next

morning. Viral supernatant was collected 48 hours post transfection, clarified by centrifugation at

4000 rpm for 5mins, and aliquoted prior to storage at -80ºC. Vero-CCL81 and 293T cells were

transduced in a 6-well plate with the prepared lentiviral constructs. Two days after transduction,

these cells were expanded into a 10cm plate and placed under selection with puromycin (for

ACE2 transduced cells) or blasticidin (for TMPRSS2 transduced cells). 293T and Vero-CCL81

cells were selected with 2 or 10µg/mL of puromycin, respectively. For blasticidin, 293T were

selected with 5µg/mL and Vero-CCL81 cells were selected with 15µg/ml. To generate ACE2

and TMPRSS2 expressing 293T cells, 293T-ACE2 cells were transduced with the VSV-G

pseudotyped lentivirus packaging TMPRSS2. These cells were subsequently selected with

5µg/mL blasticidin. Low passage stock of each cell line generated were immediately frozen

down using BamBanker (Fisher Scientific; NC9582225). Single cell, isogenic clones were

isolated via serial dilution in a 96 well plate. Wells with only a single cell were grown up and

eventually expanded while under selection.

Pseudovirus production and titering

We provide detailed production and titering protocols in the supplementary text (Supplementary

Methods). Briefly, 293T producer cells were transfected to overexpress SARS-CoV-2 or VSV-G

glycoproteins. For background entry with particles lacking a viral surface glycoprotein, pCAGG

empty vector was transfected into 293T cells. Approximately 8 hours post transfection, cells

were infected with the VSVΔG-rLuc reporter virus for 2 hours, then washed with Dulbecco's

phosphate-buffered saline (DPBS). Two days post infection, supernatants were collected and

clarified by centrifugation at 1250 rpm for 5mins. Upon collection, a small batch of VSVΔG-

rLuc particles bearing the CoV2pp were then treated with TPCK-treated trypsin (Sigma-Aldrich;

T1426-1G) at room temperature for 15 minutes prior to inhibition with soybean trypsin inhibitor

(SBTI) (Fisher Scientific; 17075029). Particles were aliquoted prior to storage in -80ºC to avoid

multiple freeze-thaws.

To titer these pseudoviruses, 20,000 Vero-CCL81 cells were seeded in a 96 well plate 20-24hrs

prior to infection. A single aliquot of BALDpp, CoV2pp, and VSV-Gpp were used for infections

and titrations were performed in technical triplicates. At 18-22 hours post infection, the infected

cells were washed with DPBS, lysed with passive lysis buffer, and processed for detection of

Renilla luciferase. The Cytation3 (BioTek) was used to read luminescence. Additional details

can be found in Supplementary Methods.

Collection of producer cells and concentration of pseudotyped particles

Cell lysates were collected from producer cells with 10mM EDTA in DPBS. Cells were

subsequently lysed with radioimmunoprecipitation assay (RIPA) buffer (Thermo Scientific,

89900) containing protease inhibitor (Thermo Scientific, 87785) for 30 minutes on ice. Lysates

were centrifuged at 25,000 × g for 30 minutes at 4°C, and the supernatants were collected and

stored at −80°C. Total protein concentrations were determined by the Bradford assay. For viral

pseudoparticles, 10 mL of designated viral particles was concentrated via 20% sucrose cushion

(20% sucrose in DPBS), Amicon Ultra centrifugal filter (100 kDa cutoff, Millipore Sigma,

UFC910024), or PEG precipitation (Abcam, ab102538). Concentrated viral particles were

resuspended in 300µL of PBS or Opti-MEM for further analysis.

Western blots

All protein samples were run under reduced conditions by dilution in 6X SDS containing

dithiothreitol (DTT) and 5% beta-mercaptoethanol (Fisher Scientific; ICN19483425). The

protein was subsequently incubated in a heating block at 95ºC for 15mins, run on a 4-15% SDS-

PAGE gel, and transferred to polyvinylidene difluoride (PVDF) membranes (Bio-Rad).

Membranes were blocked with phosphate-buffered saline blocking buffer (LI-COR, 927-

700001), and then probed with the indicated antibodies. Antibodies against SARS-CoV2 (2B3E5

from Dr. Thomas Moran and GTX632604 from GeneTex), ACE2 (66699-1-Ig from Proteintech

and Rb ab108252 from abcam), VSV-G (A00199 from Genescript), VSV-M (EB0011 from

Kerafast), anti-HA (NB600-363 from Novus), and CoX IV (926-42214 from LI-COR) were

used. For secondary staining, membranes were washed and incubated with the appropriate Alexa

Fluor 647-conjugated anti-mouse antibody or Alexa Fluor 647-conjugated anti-rabbit antibody.

Alexa Fluor 647 was detected using the ChemiDoc MP imaging system (Bio-Rad). Relative

ACE2 or TMPRSS2 abundance was calculated by first normalizing abundance relative to

GAPDH expression, then normalizing to wild type expression.

RNA extraction and qPCR for ACE2 and TMPRSS2 expression

Total RNA was extracted from cells using Direct-zol[TM] RNA Miniprep kit (Zymol, R2051), and

reverse transcription (RT) was performed with the Tetro[TM] cDNA Synthesis kit (Bioline, BIO-

65043) and random hexamers. RT PCR was performed with the SensiFAST™ SYBR &

Fluorescein Kit (Bioline, BIO-96005). For qPCRs, HPRT forward (5'-

ATTGTAATGACCAGTCAACAGGG-3') and reverse (5'-GCATTGTTTTGCCAGTGTCAA-

3') primers, ACE2 forward (5'-GGCCGAGAAGTTCTTTGTATCT-3') and reverse (5'-

CCCAACTATCTCTCGCTTCATC-3') primers, and TMPRSS2 forward (5'-

CCATGGATACCAACCGGAAA-3') and reverse (5'-GGATGAAGTTTGGTCCGTAGAG-3')

primers were utilized. Samples were read on the CFX96 Touch Real-Time PCR Detection

System (Biorad). For qPCR forward and reverse primers were utilized. The qPCR was

performed in duplicates for each sample and results were calculated using $2^{-\Delta\Delta CT}$ with

normalization to the HPRT housekeeping gene control and further normalization to the 293T

parental cells.

Sera acquisition

All patient sera were acquired after approval by the respective institutional review boards and/or

equivalent oversight bodies (Bioethics Committee, Independent Ethics Committee) are indicated:

(1) Mount Sinai Hospital Institutional Review Board (New York, USA), (2) Louisiana State

University Health Sciences Center – Shreveport (LSUHS, Louisiana, USA), and (3) Fundacion

Instituto Leloir-CONICET, Universidad Nacional de San Martin, Laboratorio Lemos SRL,

Universidad de Buenos Aires (COVIDAR Argentina Consortium, Buenos Aires, Argentina).

Samples were de-identified at the source institutions or by the respective PIs of the IRB

approved protocols for sample collection before analysis performed in this study. All necessary

patient/participant consent has been obtained and the appropriate institutional forms have been

archived.

ELISAs and Live Virus Neutralization

Spike ELISAs for patient sera from the Krammer lab were performed in a clinical setting using

the two-step protocol previously published (Mount Sinai Hospital). Briefly, this involves

screening patient sera (at a 1:50 dilution) with sRBD and samples determined to be positive were

further screened at 5 dilutions for reactivity to spike ectodomain. All 36 samples were screened

in this manner, but a subset of 15 samples were further screened for IgG and IgM binding

antibodies to spike ectodomain. The protocol from Stadlbauer et al[106] was modified slightly to

start from a 1:300 and end at a 1:24300 dilution of sera. IgG and IgM antibodies were detected

with secondary antibodies conjugated to HRP (Millipore AP101P for anti-Human IgG and

Invitrogen A18841 for anti-Human IgM). Background was subtracted from the OD values,

samples were determined to be positive if ≥3 fold over the negative control and AUC was

calculated in PRISM. ELISAs performed by the LSUHS group utilized sRBD with a 1:50

dilution of patient sera to screen all samples followed by spike ectodomain with patient sera at a

1:100 dilution. Background subtracted OD values are reported for both sets of ELISAs. ELISAs

performed by the COVIDAR group utilized a mixture of sRBD and spike ectodomain for

samples serially diluted from 1:50 to 1:6400. AUC were calculated as described above.

All live virus neutralizations were performed at biosafety-level-3 (BSL-3) using the USA-

WA/2020 isolate of SARS-CoV-2 as described in Amanat et al[73]. Briefly, ~600 50% tissue

culture infectious doses (TCID50) of virus was incubated with a serial dilution of patient sera for

1hr at 37ºC prior to infection of Vero-E6 cells. Forty-eight hours post infection, cells were fixed

in 10% PFA and stained with mouse anti-SARS-CoV nucleoprotein antibody. This was

subsequently detected by the addition of HRP-conjugated goat anti-mouse IgG and

SIGMAFAST OPD. The BioTek Synergy 4 plate reader was used to measure OD490, which was

subsequently used to calculate microneutralization (MN) titers. The samples with live virus MN

titers were a part of a larger study by Krammer and colleagues looking at the longitudinal

dynamics of the humoral immune response. This study was recently posted on medRxiv.[35] We

obtained permission from the authors to utilize a random subset of sera samples from their study

and their associated MN titers for validation studies with our CoV2pp based virus neutralization

assay.

Neutralization studies with patient sera, soluble RBD, or Nafamostat-mesylate

De-identified sera were obtained with IRB approval to use for research purposes. Unless

otherwise noted, all patient sera were heat inactivated at 56ºC for 30 minutes, and serially diluted

in DMEM+10%FCS when performing virus neutralization assays (VNAs). For groups receiving

our CoV2pp, we recommended titrating our stocks first to determine the linear dynamic range

that would be useful for VNAs done in their labs. As a quality control, we only send out CoV2pp

stocks that give signal:noise ratios of at least 100-fold over BALDpp when diluted 4-fold in 100

μl total infection volume in 96-well plate format. For the VNAs performed in our lab (ISMMS-

1), a pre-titrated amount of pseudotyped particles (diluted to give approximately 10^5 RLU) was

incubated with a 4-fold serial dilution of patient sera for 30 minutes at room temperature prior to

infection of Vero-CCL81 cells seeded the previous day. For sRBD or Nafamostat inhibition, a

pre-titrated amount of pseudotyped particle dilution was mixed with the protein or compound

and added to cells immediately after. Approximately 20 hours post infection, cells were

processed for detection of luciferase activity as described above. Our recommendations to

generate a robust neutralization curve were to do an 8-point serial dilution curve with each point

done in triplicate. Raw luminometry data were obtained from labs that volunteered VNA results

from at least 12 patient samples and analyzed as indicated below.

Method modifications from the three contributing labs are as follows. Serum neutralizations by

LSUHS (Kamil and Ivanov) were performed by first diluting 4-fold in 100 µl total volume then

diluting via a 3-fold serial dilution. Cell lysates were transferred to a white walled 96 well plate,

then the Promega Renilla luciferase assay kit was utilized to detect luciferase. Plates were read

on a Tecan SPARK plate reader by collecting total luminescence signal for 10 seconds. ISMMS-

2 (Hioe) began neutralizations at a 10-fold dilution and proceeded with a 4-fold serial dilution.

Plates were read on a black walled 96 well plate using the Renilla Glo substrate (Promega,

E2720) with a 1 second signal integration time. COVID-19 samples were provided to ISMMS-2

by the Clinical Pathology Laboratory at ISMMS or from an IRB-approved study at the James J.

Peters VA Medical Center. COVIDAR (Gamarnik) began at either an 8-fold or 16-fold dilution

then continuing with either a 3-fold or 2-fold serial dilution respectively. White, F-bottom

Lumitrac plates (Greiner, 655074) plates were read via the GloMax® Navigator Microplate

Luminometer (Promega, GM200) using the ONE-Glo[TM] Luciferase Assay System (Promega,

E6110).

Inhibitory Concentration Calculations and other R packages used

Relative inhibitory concentrations (IC) values were calculated for all patient sera samples by

modeling a 4-parameter logistic regression with drm in the R drc package.[112] For examples, a

relative inhibitory concentration of 50% (IC50) is calculated as the midway point between the

upper and lower plateaus of the curve. Absolute inhibitory concentration (absIC) was calculated

as the corresponding point between the 0% and 100% assay controls. For example, the absIC50

would be the point at which the curve matches inhibition equal to exactly 50% of the 100% assay

control relative to the assay minimum (0%).[113] As a result, sera samples that are non-neutralizing

or minimally neutralizing may have lower plateaus indicating they cannot reach certain absolute

inhibitory concentrations, such as an absIC90 or absIC99. R was also used to generate the

heatmaps presented in Fig. 4B and Fig. 5A as well as the plots in Fig. 4D, Fig. 5C, and

Supplemental Fig. 7.

Acknowledgements

In addition to the three labs that provided data for this paper, we acknowledge the generosity of

the many labs that independently verified our CoV2pp VNA. We want to especially

acknowledge the entirety of the Lee Lab, whom, during a pandemic, dropped all other work and

pooled resources together in pursuit of developing this and other tools that are providing support

to other labs doing COVID-19 work. Moreover, we acknowledge the generosity of the patients

that donated blood for use in convalescent sera studies and for further use in research studies

similar to the work presented here.

The authors acknowledge the following funding: KYO and CS were supported by Viral-Host

Pathogenesis Training Grant T32 AI07647; KYO was additionally supported

by F31 AI154739. SI and CTH were supported by postdoctoral fellowships from CHOT-SG

(Fukuoka University, Japan) and the Ministry of Science and Technology (MOST, Taiwan),

respectively. BL acknowledges flexible funding support from NIH grants R01 AI123449, R21

AI1498033, and the Department of Microbiology and the Ward-Coleman estate for endowing the

Ward-Coleman Chairs at the ISMMS. JPK and SSI acknowledge funding from a LSUHS

COVID-19 intramural grant. JPK and SSI acknowledge additional funding from NIH grants

AI116851 and AI143839, respectively. This work was further supported by the Microbiology

Laboratory Clinical Services at the Mount Sinai Health System and the Mount Sinai Health

System Translational Science Hub, NIH grant U54TR001433 to the Department of Medicine of

the ISMMS to SZP. We also acknowledge funding from the Department of Veterans Affairs

Merit Review Grant I01BX003860 (CEH, SZP, and JK), Research Career Scientist Award

1IK6BX004607 (CEH), and NIH grant AI139290 (CEH, SZP). We thank Randy A. Albrecht for

oversight of the conventional BSL3 biocontainment facility. Work in the Krammer laboratory

was partially supported by the NIAID Centers of Excellence for Influenza Research and

Surveillance (CEIRS) contract HHSN272201400008C (FK), Collaborative Influenza Vaccine

Innovation Centers (CIVIC) contract 75N93019C00051 (FK) and the generous support of the

JPB foundation, the Open Philanthropy Project (#2020-215611) and other philanthropic

donations.

 Figures/Figure Legends:

 Figure 1. Production of VSVΔG-rLuc bearing SARS-CoV-2 spike glycoprotein (A)

 Overview of VSVΔG-rLuc pseudotyped particles bearing CoV-2 spike (top panel) with

 annotated spike glycoprotein domains and cleavage sites (bottom panel). As mentioned in the

 text, we refer to SARS-CoV as SARS-CoV-1 for greater clarity. **(B)** VSV-ΔG[Rluc]

 pseudotyped particles (VSVpp) bearing the Nipah virus receptor binding protein alone (NiV-

 RBPpp), SARS-CoV-2-S (CoV2pp), or VSV-G (VSV-Gpp) were titered on Vero-CCL81 cells

 using a 10-fold serial dilution. Symbols represent the mean +/- SEM (error bars) of each titration

 performed in technical triplicates. **(C)** Expression of the indicated viral glycoproteins on

 producer cells and their incorporation into VSVpp. Western blots performed as described in

 Methods using anti-S1 or anti-S2 specific antibodies. **(D)** CoV2pp entry is inhibited by soluble

 receptor binding domain (sRBD) derived from SARS-CoV-2-S. CoV2pp and VSV-Gpp

 infection of Vero-CCL81 cells was performed as in (B) in the presence of the indicated amounts

 of sRBD. Neutralization curves were generated by fitting data points using a variable slope, 4-

 parameter logistics regression curve (robust fitting method). The last point (no sRBD) was fixed

 to represent 100% maximal infection. Each replicate from an experiment performed in duplicate

 is shown. The calculated IC50 for sRBD neutralization of CoV2pp is 4.65µg/mL.

 Figure 2. CoV2pp entry is enhanced by trypsin treatment. (A) Optimizing trypsin treatment

 conditions. Supernatant containing CoV2pp were trypsin-treated at the indicated concentrations

 for 15 min. at room temperature prior to the addition of 625 µg/mL of soybean trypsin inhibitor

 (SBTI). These particles were then titered on Vero-CCL81 cells in technical triplicates. Data

shown as mean +/- SEM. **(B)** Dilution in serum free media (SFM, DMEM only) provides the

highest signal:noise ratio for trypsin-treated CoV2pp entry. Particles were diluted 1:10 in Opti-

MEM, SFM, or DMEM+10%FBS prior to infection of Vero-CCL81 cells and spinoculation as

described in Fig. 1D. Cells infected without spinoculation show approximately 3x less

signal:noise ratios (Supplemental Fig. 2). **(C)** Addition of soybean trypsin inhibitor at the time of

infection reduces trypsin treated particle entry. This was performed in technical triplicates for

two independent experiments. Shown are the combined results with error bars indicating SEM

and **** indicating a p-value <0.0001. (D) Schematic showing overall view of how protease

priming and SBTI treatment is working to enhance CoV2pp entry.

Figure 3. Trypsin-treated CoV2pp depend on ACE2 and TMPRSS2 for entry. (A) Parental

and TMPRSS2 or ACE2 transduced VeroCCL81 cells were infected with the indicated

pseudotyped viruses. All particles were diluted in serum free media in order to be within the

linear range for the assay. Normalized infectivity data is presented as fold-over Vero-CCL81-

WT for the various VSVpp shown. VSV-Gpp served as an internal control for the intrinsic

permissiveness of various cell lines to VSV mediated gene expression. Data is presented as mean

+/- SEM from two independent experiments done in technical triplicates. *, p <0.05, **, p-

<0.01, and ****, p <0.0001. **(B)** Western blot of wild type and transduced Vero CCL81 cells.

The numbers below each column show the relative ACE2 abundance was measured by

densitometry and normalized as described in Methods.

Figure 4. CoV2pp viral neutralization assay and absIC50/80 versus spike binding of patient

sera. (A) 36 patient sera screened for CoV2pp neutralization. CoV2pp were used to infect Vero-

CCL81 cells in the presence of a 4-fold serial dilution of patient sera as described in the

Methods. Samples in light purple do not neutralize CoV2pp. Neutralization curves were fit using

a variable slope, 4-parameter logistics regression curve with a robust fitting method. **(B)** The

same 36 samples are shown as a neutralization heat map, which were generated in R as described

in the Methods. Here, red represents complete neutralization and blue represents no

neutralization. Samples are sorted by the average from the first four dilutions with the most

neutralizing samples on the left. **(C)** Correlation of CoV2pp neutralization titers to spike binding

(ELISA AUC) and live virus microneutralization (MN) activity. Absolute IC50 (absIC50, top)

and IC80 (absIC80, bottom) for CoV2pp neutralizations and live virus MNs were calculated in R

using a 4-parameter logistic regression model as described in the Methods. Presented are the

added IgG and IgM ELISA AUC. AUC and live virus neutralizations were performed as

described in the Methods. Presented are the r and p value from a simple linear regression. **(D)**

Positive serum samples and their CoV2pp reciprocal absIC50 (top) and absIC80 (bottom). The

IC50 graph is colored and ordered to display samples with low, average, or high IC50 as blue,

grey or red circles, respectively. The IC80 graph below retains the coloring from the IC50 graph,

but the samples are now ordered from left to right to show samples with the lowest to highest

IC80 values. Tukey box and whisker plots show median with interquartile range (IQR) and

whiskers extending to 1.5x the IQR. All points outside that range are depicted.

Figure 5. CoV2pp viral neutralization assay validated against patient sera by external

groups. (A) Patient sera neutralization of CoV2pp for 88 samples run by three different

independent groups. This is visualized as in Fig. 4B where red represents complete neutralization

and blue represents no neutralization. **(B)** Correlations of CoV2pp reciprocal AbsIC80 to spike

ELISAs. AbsIC80 was calculated as previously described in Fig. 4C. For LSUHS ELISAs, spike

ectodomain was used and sera was diluted to a 1:100 dilution. For the COVIDAR ELISAs, a

mixture of sRBD and spike was utilized as previously described[114] and AUC was calculated as

described in the Methods. **(C)** Summary AbsIC80 of 89 positive sera CoV2pp neutralizations.

Samples from all 4 groups are depicted on the X-axis. AbsIC80 was calculated as described in

Fig. 4C and Tukey box and whisker plots are shown as described in Fig. 4D.

Table 1. Comparison of ELISA endpoint titers to CoV2pp neutralization. Presented are the

clinical lab ELISA endpoint titers from samples discussed in Fig. 4A. Descriptive statistics were

generated in PRISM using data presented in Fig. 5C. Values highlighted in red are of interest and

are discussed further in the Results.

Figure 6. 293T stably transduced with ACE2 and TMPRSS2 (293T-ACE2+TMPRSS2) are

ultra-permissive for SARS-CoV-2pp infection. (A) Infection of 293T cells lines transduced to

stably express, TMPRSS2, ACE2, or both. Cell lines were generated as described in the

Materials and Methods. A single dilution of particles was used to infect cells prior to

spinoculation as described in the Methods. Infections were done in technical triplicates.

Presented are the aggregated results from two independent replicates and error bars show SEM.

For statistics, ns = not significant, ** is a p-value <0.01, and **** is a p-value <0.0001. **(B)**

Western blot of ACE2 expression in 293T cell lines. This was performed as described in the

methods and the values below each column represents the relative abundance of ACE2. **(C)**

Normalized CoV2pp entry into single cell clones. Entry was normalized to the wild type parental

cell line and further normalized to VSV-G entry. Presented are the average of one experiment in

technical triplicates. Error bars show the median and interquartile range. Raw entry data for each

cell clone is shown in Supplementary Fig. 9A **(D)** Entry inhibition of CoV2pp in by Nafamostat

mesylate, a serine protease inhibitor. Nafamostat was mixed with CoV2pp (left panel) or VSV-

Gpp (right panel) prior addition to cells. Shown are the results from one experiment in technical

triplicates. Data are presented as described in Fig. 4A and error bars show SEM.

Figure 7. Ultra-permissive 293T-ACE2+TMPRSS2 cell clones retains the same phenotypic

sensitivity to convalescent COVID-19 sera. (A) Selection of pooled sera samples. Results from

Fig. 4A are reproduced here for the reader's convenience. Presented are the subset of samples

that were pooled for use in viral neutralization assays (VNAs) in the adjacent panel. **(B)** Vero

CCL81 and transduced 293T cells were used for VNAs. Sera previously shown to be negative,

weakly positive, or strongly positive for CoV2pp neutralizations were selected to be pooled in

equal volumes. These were subsequently used for VNAs, which were performed and presented

as described in Fig. 4A. Notably, these VNAs were performed in the absence of exogenous

trypsin or spinoculation.

Supplemental Table 1. Descriptive statistics for CoV2pp neutralizations across 4 groups.

Presented are the descriptive statistics from the CoV2pp neutralizations shown in Fig. 5C.

Absolute IC50, 80, and 90 were calculated as previously described in the Methods. Median and

other percentiles presented here were calculated in PRISM.

Supplemental Figure 1. Expression spike glycoproteins in different growth media.

Expression of CoV-2 spike in producer cells shows modestly increased cleavage in the presence

of reduced or absent FBS. Western blots performed as described in the Methods.

Supplemental Figure 2. Dilution of CoV2pp in the absence of serum free media produces

the highest signal:noise for trypsin treated CoV2pp. Performed as described in Fig. 2B, but

was done in the absence of spinoculation. Presented are the results from an experiment in

technical triplicate and error bars show the SEM.

Supplemental Figure 3. Sera neutralization in the absence of 10% FBS and optimization of

neutralizations. (A) Negative sera potently inhibits trypsin treated CoV2pp. CoV2pp were

diluted in serum free media (SFM), then pooled negative sera and a positive serum were used to

neutralize entry. An aliquot was heat inactivated (HI) for 1hr in a 56ºC water bath prior to use.

Neutralizations were performed as described in the methods. Data are presented on a linear (left

panel) and log scale (right panel). Each replicate from one experiment in technical duplicates are

shown and neutralization curves were generated as done in Fig. 1D. **(B)** Sera neutralizations

were performed with untreated CoV2pp (left panel) or CoV2pp treated with trypsin (middle

panel). Both particles were diluted in DMEM+10% FBS and neutralization curves are presented

as described above. VSV-G was not neutralized by the negative or positive sera (right panel). **(C)**

sRBD neutralizes CoV2pp equivalently across all conditions tested. Data presented in Fig. 1D

(i.e. the untreated CoV2pp) is duplicated here. Neutralization curves are presented as described

above.

Supplemental Figure 4. Live SARS-CoV-2 microneutralization curves. Live virus

microneutralization curves were performed as described in the materials and methods.

Neutralizations were performed in technical duplicates and shown are SD. Data are presented as

in Fig. 4A and fit to a variable slope, 4-parameter logistics curve.

Supplemental Figure 5. Neutralization curves from the LSUHS, ISMMS-2, and COVIDAR

labs. The neutralization curves presented here were generated from the same data used to create

the neutralization heat maps shown in Figure 5A. The curves were fit using a variable slope, 4

parameter logistics model (robust regressions fitting). The ISMMS-2 group (top left panel) and

COVIDAR group (bottom panels) perform neutralizations in technical triplicates. The LSUHS

group (top right panel) performed their neutralizations in technical quadruplicates.

Supplemental Figure 6. Relationship of ELISA endpoint titers and CoV2pp reciprocal

AbsIC50, 80, and 90. Presented are the clinical lab ELISA endpoint titers and CoV2pp

neutralization absIC values. There are 11 samples with ELISA endpoints of 320, 8 samples with

ELISA endpoints of 960, and 11 samples with ELISA endpoints of 2880. Absolute (Abs) IC50,

80, and 90 were calculated as described in the Methods. Error bars (blue) show median and

interquartile range, red and black dotted lines represent the median and 75th percentile for each

AbsIC value as calculated in Supplemental table 1. The gray shaded region indicates samples

that fall above the 75th percentile. One sample with an ELISA endpoint of 320 has an absIC90

below 10^{-1} and thus is not present on the absIC90 graph.

Supplemental Figure 7. Ordered CoV2pp absolute IC50 (top), IC80 (middle) and IC90

(bottom) plots from all four groups. As previously presented in Fig. 4D, the IC50 graph is

colored and ordered to display samples with low, average or high IC50 as blue, grey or red

circles, respectively. The colors from the IC50 graphs are retained in the IC80 and IC90 graphs,

which are ordered from lowest to highest neutralization. Tukey box and whisker plots are

presented to the right of the graph. These show findings that are consistent to the observations in

Fig. 4D, suggesting that not all samples with high IC50s have potent IC80s or IC90s.

Supplemental Figure 8. Comparison of CoV2pp Absolute IC values across all 4 groups.

CoV2pp Absolute IC values were calculated as previously described in Fig. 4C. Shown are the

CoV2pp absolute IC50 (left panel), IC80 (middle panel) and IC90 (right panel) from all four

groups with error bars (blue) showing the median and interquartile range. The red dotted line

presents the median from the aggregated positive neutralization samples as reported in

Supplemental Table 1. The black dashed line indicates neat serum and the shaded gray region

highlights samples that fall below this value. An ordinary one-way ANOVA with Dunnett's

correction for multiple comparisons was performed for statistics. This analysis revealed no

statistically significant difference between the Absolute IC values obtained across the 4 groups.

There were notable outliers in this data set, including individuals that show poor neutralization

(i.e. the 3 samples in the IC50 plot from LSUHS) and an individual that showed exceptionally

potent neutralization (i.e. the sample in all plots from ISMMS-2). One sample from ISMMS-1

had an absIC90 below 10^{-1} and, as a result, is not presented on the absIC90 graph.

Supplemental Figure 9. Screening and validation of single cell clones. (A) Raw RLU values

from infection of the indicated cells by BALDpp, CoV2pp, or VSV-Gpp. Parental cell lines, bulk

transduced cell lines, and isogenic cell lines are indicated. Highlighted in blue and purple are the

ultra-permissive clones stably expressing ACE2 or ACE2 and TMPRSS2, respectively.

Presented are the results from an experiment in technical triplicates and error bars show the

SEM. (B) Expression of ACE2 and TMPRSS2 in select cell lines. RNA extraction and qPCR

performed as described in the Methods prior to calculating $2^{-\Delta\Delta CT}$, which was then normalized to

the 293T parental cells. Of interest are the clones highlighted in blue and purple, which were

transduced to stably express ACE2 or ACE2 and TMPRSS2.

Supplemental Figure 10. CoV2pp were titered on Vero-CCL81 cells, 293T-ACE2 clone 5-7,

and 293T-ACE2-TMPRSS2 clone F8-2. Titrations were performed with untreated CoV2pp and

without spinoculation. Presented are the results from technical triplicates and bars show the

SEM.

References

1. Rehman, S. U., Shafique, L., Ihsan, A. & Liu, Q. Evolutionary trajectory for the emergence of novel coronavirus SARS-CoV-2. *Pathogens* **9**, 1–12 (2020).

2. Peiris, J. S. M., Guan, Y. & Yuen, K. Y. Severe acute respiratory syndrome. *Nat. Med.* **10**, S88–S97 (2004).

3. Center for Disease Control. *Revised U.S. Surveillance Case Definition for Severe Acute Respiratory Syndrome (SARS) and Update on SARS Cases - United States and Worldwide, December 2003*. (2003).

4. World Health Organization. *Novel Coronavirus (2019-nCoV): situation report, 19.* (2020).

5. Petherick, A. Developing antibody tests for SARS-CoV-2. *Lancet* **395**, 1101–1102 (2020).

6. Schmidt, F. *et al.* Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. *J. Exp. Med.* **217**, (2020).

7. Dieterle, M. E. *et al.* A Replication-Competent Vesicular Stomatitis Virus for Studies of SARS-CoV-2 Spike-Mediated Cell Entry and Its Inhibition. *Cell Host Microbe* (2020). doi:10.1016/j.chom.2020.06.020

8. Nie, J. *et al.* Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2. *Emerg. Microbes Infect.* **9**, 680–686 (2020).

9. Case, J. B. *et al.* Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2. *bioRxiv* (2020). doi:https://doi.org/10.1101/2020.05.18.102038

10. Jackson, L. A. *et al.* An mRNA Vaccine against SARS-CoV-2 — Preliminary Report. *N.*

1014   *Engl. J. Med.* (2020). doi:10.1056/NEJMoa2022483

1015 11. Folegatti, P. M. *et al.* Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine

1016   against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised

1017   controlled trial. *Lancet* 1–13 (2020). doi:10.1016/S0140-6736(20)31604-4

1018 12. Zhu, F. C. *et al.* Safety, tolerability, and immunogenicity of a recombinant adenovirus

1019   type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-

1020   in-human trial. *Lancet* **395**, 1845–1854 (2020).

1021 13. Mulligan, M. J. *et al.* Phase 1/2 Study to Describe the Safety and Immunogenicity of a

1022   COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age:

1023   Interim Report. *medRxiv* (2020). doi:10.1101/2020.06.30.20142570

1024 14. Sahin, U. *et al.* Concurrent human antibody and TH1 type T-cell responses elicited by a

1025   COVID-19 RNA vaccine. *medRxiv* (2020). doi:10.1101/2020.07.17.20140533

1026 15. Keech, C. *et al.* First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein

1027   Nanoparticle Vaccine. *medRxiv* 2020.08.05.20168435 (2020).

1028   doi:10.1101/2020.08.05.20168435

1029 16. Duan, K. *et al.* Effectiveness of convalescent plasma therapy in severe COVID-19

1030   patients. *Proc. Natl. Acad. Sci.* **117**, 9490–9496 (2020).

1031 17. Shen, C. *et al.* Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent

1032   Plasma. *JAMA* **323**, 1582 (2020).

1033 18. Li, L. *et al.* Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in

1034   Patients With Severe and Life-threatening COVID-19. *JAMA* **324**, 460 (2020).

1035 19. Joyner, M. J. *et al.* Early safety indicators of COVID-19 convalescent plasma in 5,000

1036   patients. *J. Clin. Invest.* (2020). doi:10.1172/JCI140200

20.   Joyner, M. J. *et al.* Evidence favouring the efficacy of convalescent plasma for COVID-19

therapy. *medRxiv* 2020.07.29.20162917 (2020). doi:10.1101/2020.07.29.20162917

21.   Hartman, W., Hess, A. S. & Connor, J. P. Hospitalized COVID-19 patients treated with

Convalescent Plasma in a mid-size city in the midwest. *medRxiv* (2020).

doi:10.1101/2020.06.19.20135830

22.   Jin, C. *et al.* Treatment of Six COVID-19 Patients with Convalescent Plasma. *medRxiv*

(2020). doi:10.1101/2020.05.21.20109512

23.   Rasheed, A. M. *et al.* The therapeutic effectiveness of Convalescent plasma therapy on

treating COVID-19 patients residing in respiratory care units in hospitals in Baghdad,

Iraq. *medRxiv* 2020.06.24.20121905 (2020). doi:10.1101/2020.06.24.20121905

24.   Gharbharan, A. *et al.* Convalescent Plasma for COVID-19. A randomized clinical trial.

medRxiv 2020.07.01.20139857 (2020). doi:10.1101/2020.07.01.20139857

25.   Martinez-Resendez, M. F. *et al.* Initial experience in Mexico with convalescent plasma in

COVID-19 patients with severe respiratory failure, a retrospective case series. *medRxiv*

2020.07.14.20144469 (2020). doi:10.1101/2020.07.14.20144469

26.   Zhang, B. *et al.* Treatment With Convalescent Plasma for Critically Ill Patients With

Severe Acute Respiratory Syndrome Coronavirus 2 Infection. *Chest* **158**, e9–e13 (2020).

27.   Ahn, J. Y. *et al.* Use of Convalescent Plasma Therapy in Two COVID-19 Patients with

Acute Respiratory Distress Syndrome in Korea. *J. Korean Med. Sci.* **35**, (2020).

28.   Pei, S. *et al.* Convalescent Plasma to Treat COVID-19: Chinese Strategy and Experiences.

medRxiv (2020). doi:10.1101/2020.04.07.20056440

29.   Ye, M. *et al.* Treatment with convalescent plasma for COVID-19 patients in Wuhan,

China. *J. Med. Virol.* 1–12 (2020). doi:10.1002/jmv.25882

30.   Zeng, Q.-L. *et al.* Effect of Convalescent Plasma Therapy on Viral Shedding and Survival

1061   in Patients With Coronavirus Disease 2019. *J. Infect. Dis.* **222**, 38–43 (2020).

1062   31.   Salazar, E. *et al.* Treatment of Coronavirus Disease 2019 (COVID-19) Patients with

1063   Convalescent Plasma. *Am. J. Pathol.* **190**, 1680–1690 (2020).

1064   32.   H Liu, S. T. *et al.* Convalescent plasma treatment of severe COVID-19: A matched

1065   control study. *medRxiv* (2020). doi:10.1101/2020.05.20.20102236

1066   33.   Perotti, C. *et al.* Mortality reduction in 46 severe Covid-19 patients treated with

1067   hyperimmune plasma. A proof of concept single arm multicenter interventional trial co-

1068   first authors with equal contribution. *medRxiv* (2020). doi:10.1101/2020.05.26.20113373

1069   34.   Ni, L. *et al.* Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in

1070   COVID-19 Convalescent Individuals. *Immunity* **52**, 971–977 (2020).

1071   35.   Stadlbauer, D. *et al.* Seroconversion of a city: Longitudinal monitoring of SARS-CoV-2

1072   seroprevalence in New York City. *medRxiv* (2020). doi:10.1101/2020.06.28.20142190

1073   36.   Bosch, B. J., van der Zee, R., de Haan, C. A. M. & Rottier, P. J. M. The Coronavirus

1074   Spike Protein Is a Class I Virus Fusion Protein: Structural and Functional Characterization

1075   of the Fusion Core Complex. *J. Virol.* **77**, 8801–8811 (2003).

1076   37.   Li, F. Structure, Function, and Evolution of Coronavirus Spike Proteins. *Annu. Rev. Virol.*

1077   **3**, 237–261 (2016).

1078   38.   Wrapp, D. *et al.* Cryo-EM structure of the 2019-nCoV spike in the prefusion

1079   conformation. *Science (80-.).* **367**, 1260–1263 (2020).

1080   39.   Letko, M., Marzi, A. & Munster, V. Functional assessment of cell entry and receptor

1081   usage for SARS-CoV-2 and other lineage B betacoronaviruses. *Nat. Microbiol.* **5**, 562–

1082   569 (2020).

1083   40.   Hoffmann, M. *et al.* SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is

1084   Blocked by a Clinically Proven Protease Inhibitor. *Cell* **181**, 271-280.e8 (2020).

1085   41.   Hamming, I. *et al.* Tissue distribution of ACE2 protein, the functional receptor for SARS

1086   coronavirus. A first step in understanding SARS pathogenesis. *J. Pathol.* **203**, 631–637

1087   (2004).

1088   42.   Glowacka, I. *et al.* Evidence that TMPRSS2 Activates the Severe Acute Respiratory

1089   Syndrome Coronavirus Spike Protein for Membrane Fusion and Reduces Viral Control by

1090   the Humoral Immune Response. *J. Virol.* **85**, 4122–4134 (2011).

1091   43.   Menachery, V. D. *et al.* Trypsin Treatment Unlocks Barrier for Zoonotic Bat Coronavirus

1092   Infection. *J. Virol.* **94**, (2019).

1093   44.   Shang, J. *et al.* Cell entry mechanisms of SARS-CoV-2. *Proc. Natl. Acad. Sci.* **117**,

1094   11727–11734 (2020).

1095   45.   Matsuyama, S. *et al.* Efficient Activation of the Severe Acute Respiratory Syndrome

1096   Coronavirus Spike Protein by the Transmembrane Protease TMPRSS2. *J. Virol.* **84**,

1097   12658–12664 (2010).

1098   46.   Shulla, A. *et al.* A Transmembrane Serine Protease Is Linked to the Severe Acute

1099   Respiratory Syndrome Coronavirus Receptor and Activates Virus Entry. *J. Virol.* **85**, 873–

1100   882 (2011).

1101   47.   Mousavizadeh, L. & Ghasemi, S. Genotype and phenotype of COVID-19: Their roles in

1102   pathogenesis. *J. Microbiol. Immunol. Infect.* (2020). doi:10.1016/j.jmii.2020.03.022

1103   48.   Gallagher, T. M. & Buchmeier, M. J. Coronavirus Spike Proteins in Viral Entry and

1104   Pathogenesis. *Virology* **279**, 371–374 (2001).

49.   Simmons, G., Zmora, P., Gierer, S., Heurich, A. & Pöhlmann, S. Proteolytic activation of

the SARS-coronavirus spike protein: Cutting enzymes at the cutting edge of antiviral

research. *Antiviral Res.* **100**, 605–614 (2013).

50.   Tang, T., Bidon, M., Jaimes, J. A., Whittaker, G. R. & Daniel, S. Coronavirus membrane

fusion mechanism offers a potential target for antiviral development. *Antiviral Res.* **178**,

104792 (2020).

51.   Matsuyama, S. *et al.* Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells.

Proc. Natl. Acad. Sci. **117**, 7001–7003 (2020).

52.   Hofmann, H. *et al.* S Protein of Severe Acute Respiratory Syndrome-Associated

Coronavirus Mediates Entry into Hepatoma Cell Lines and Is Targeted by Neutralizing

Antibodies in Infected Patients. *J. Virol.* **78**, 6134–6142 (2004).

53.   Simmons, G. *et al.* Characterization of severe acute respiratory syndrome-associated

coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry. *Proc. Natl. Acad. Sci.*

U. S. A. **101**, 4240–4245 (2004).

54.   Yang, Z.-Y. *et al.* pH-Dependent Entry of Severe Acute Respiratory Syndrome

Coronavirus Is Mediated by the Spike Glycoprotein and Enhanced by Dendritic Cell

Transfer through DC-SIGN. *J. Virol.* **78**, 5642–5650 (2004).

55.   Zheng, M. & Song, L. Novel antibody epitopes dominate the antigenicity of spike

glycoprotein in SARS-CoV-2 compared to SARS-CoV. *Cell. Mol. Immunol.* **17**, 536–538

(2020).

56.   Okba, N. M. A. *et al.* Severe Acute Respiratory Syndrome Coronavirus 2–Specific

Antibody Responses in Coronavirus Disease Patients. *Emerg. Infect. Dis.* **26**, 1478–1488

(2020).

57.   Zhao, J. *et al.* Antibody responses to SARS-CoV-2 in patients of novel coronavirus

disease 2019. *Clin. Infect. Dis.* (2020). doi:10.1093/cid/ciaa344

58.	Wölfel, R. *et al.* Virological assessment of hospitalized patients with COVID-2019.

Nature **581**, 465–469 (2020).

59.	To, K. K. W. *et al.* Temporal profiles of viral load in posterior oropharyngeal saliva

samples and serum antibody responses during infection by SARS-CoV-2: an observational

cohort study. *Lancet Infect. Dis.* **20**, 565–574 (2020).

60.	Wu, L.-P. *et al.* Duration of Antibody Responses after Severe Acute Respiratory

Syndrome. *Emerg. Infect. Dis.* **13**, 1562–1564 (2007).

61.	Xiao, A. T., Tong, Y. X. & Zhang, S. False negative of RT-PCR and prolonged nucleic

acid conversion in COVID-19: Rather than recurrence. *J. Med. Virol.* **30329**, jmv.25855

(2020).

62.	Xing, Y. *et al.* Post-discharge surveillance and positive virus detection in two medical

staff recovered from coronavirus disease 2019 (COVID-19), China, January to February

2020. *Eurosurveillance* **25**, 2–5 (2020).

63.	Bao, L. *et al.* Lack of Reinfection in Rhesus Macaques Infected with SARS-CoV-2.

bioRxiv (2020). doi:10.1101/2020.03.13.990226

64.	Chandrashekar, A. *et al.* SARS-CoV-2 infection protects against rechallenge in rhesus

macaques. *Science (80-.).* (2020). doi:10.1126/science.abc4776

65.	Holmes, K. V. SARS coronavirus□: a new challenge for prevention and therapy. *J. Clin.*

Invest. **111**, 1605–1609 (2003).

66.	Cavanagh, D. Coronaviruses and Toroviruses. in *Principles and Practice of Clinical*

Virology 379–397 (John Wiley & Sons, Ltd, 2009). doi:10.1002/0470020970.ch10

67.	Kellam, P. & Barclay, W. The dynamics of humoral immune responses following SARS-

1152   CoV-2 infection and the potential for reinfection. *J. Gen. Virol.* (2020).

1153   doi:10.1099/jgv.0.001439

1154   68.   Ibarrondo, F. J. *et al.* Rapid Decay of Anti–SARS-CoV-2 Antibodies in Persons with Mild

1155   Covid-19. *N. Engl. J. Med.* NEJMc2025179 (2020). doi:10.1056/NEJMc2025179

1156   69.   Wang, K. *et al.* Longitudinal dynamics of the neutralizing antibody response to SARS-

1157   CoV-2 infection. *medRxiv* doi:10.1101/2020.07.14.20151159

1158   70.   Seow, J. *et al.* Longitudinal evaluation and decline of antibody responses in SARS-CoV-2

1159   infection. *medRxiv* (2020). doi:10.1101/2020.07.09.20148429

1160   71.   Long, Q.-X. *et al.* Clinical and immunological assessment of asymptomatic SARS-CoV-2

1161   infections. *Nat. Med.* (2020). doi:10.1038/s41591-020-0965-6

1162   72.   Liu, W. *et al.* Evaluation of Nucleocapsid and Spike Protein-Based Enzyme-Linked

1163   Immunosorbent Assays for Detecting Antibodies against SARS-CoV-2. *J. Clin.*

1164   *Microbiol.* **58**, 1–7 (2020).

1165   73.   Amanat, F. *et al.* A serological assay to detect SARS-CoV-2 seroconversion in humans.

1166   *Nat. Med.* **26**, 1033–1036 (2020).

1167   74.   Caruana, G. *et al.* Diagnostic strategies for SARS-CoV-2 infection and interpretation of

1168   microbiological results. *Clin. Microbiol. Infect.* (2020). doi:10.1016/j.cmi.2020.06.019

1169   75.   Rogers, T. F. *et al.* Isolation of potent SARS-CoV-2 neutralizing antibodies and protection

1170   from disease in a small animal model. *Science (80-.).* **7520**, eabc7520 (2020).

1171   76.   Seydoux, E. *et al.* Analysis of a SARS-CoV-2-Infected Individual Reveals Development

1172   of Potent Neutralizing Antibodies with Limited Somatic Mutation. *Immunity* **53**, 98-

1173   105.e5 (2020).

77.   Wu, Y. *et al.* Identification of Human Single-Domain Antibodies against SARS-CoV-2.

Cell Host Microbe **27**, 891–898 (2020).

78.   Wec, A. Z. *et al.* Broad neutralization of SARS-related viruses by human monoclonal

antibodies. *Science (80-.).* **7424**, (2020).

79.   Manenti, A. *et al.* Evaluation of SARS-CoV-2 neutralizing antibodies using a CPE-based

colorimetric live virus micro-neutralization assay in human serum samples. *J. Med. Virol.*

jmv.25986 (2020). doi:10.1002/jmv.25986

80.   Perera, R. A. *et al.* Serological assays for severe acute respiratory syndrome coronavirus 2

(SARS-CoV-2), March 2020. *Eurosurveillance* **25**, (2020).

81.   Bohn, M. K. *et al.* Molecular, serological, and biochemical diagnosis and monitoring of

COVID-19: IFCC taskforce evaluation of the latest evidence. *Clin. Chem. Lab. Med.* **58**,

1037–1052 (2020).

82.   Özçürümez, M. K. *et al.* SARS-CoV-2 antibody testing—questions to be asked. *J. Allergy*

Clin. Immunol. **146**, 35–43 (2020).

83.   Tan, C. W. *et al.* A SARS-CoV-2 surrogate virus neutralization test (sVNT) based on

antibody-mediated blockage of ACE2-spike (RBD) protein-protein interaction. *Res. Sq.*

(2020). doi:10.21203/rs.3.rs-24574/v1

84.   Liu, L. *et al.* Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2

spike. *Nature* (2020). doi:10.1038/s41586-020-2571-7

85.   Chi, X. *et al.* A neutralizing human antibody binds to the N-terminal domain of the Spike

protein of SARS-CoV-2. *Science (80-.).* eabc6952 (2020). doi:10.1126/science.abc6952

86.   Gorse, G. J., Donovan, M. M. & Patel, G. B. Antibodies to coronaviruses are higher in

older compared with younger adults and binding antibodies are more sensitive than

neutralizing antibodies in identifying coronavirus-associated illnesses. *J. Med. Virol.* **92**,

1198   512–517 (2020).

1199   87.   Takada, A. *et al.* A system for functional analysis of Ebola virus glycoprotein. *Proc. Natl.*

1200   *Acad. Sci.* **94**, 14764–14769 (1997).

1201   88.   Negrete, O. A. *et al.* EphrinB2 is the entry receptor for Nipah virus, an emergent deadly

1202   paramyxovirus. *Nature* **436**, 401–405 (2005).

1203   89.   Avanzato, V. A. *et al.* A structural basis for antibody-mediated neutralization of Nipah

1204   virus reveals a site of vulnerability at the fusion glycoprotein apex. *Proc. Natl. Acad. Sci.*

1205   **116**, 25057–25067 (2019).

1206   90.   Zettl, F. *et al.* Rapid Quantification of SARS-CoV-2-Neutralizing Antibodies Using

1207   Propagation-Defective Vesicular Stomatitis Virus Pseudotypes. *Vaccines* **8**, 386 (2020).

1208   91.   Shirato, K., Kawase, M. & Matsuyama, S. Wild-type human coronaviruses prefer cell-

1209   surface TMPRSS2 to endosomal cathepsins for cell entry. *Virology* **517**, 9–15 (2018).

1210   92.   Wang, C. *et al.* A human monoclonal antibody blocking SARS-CoV-2 infection. *Nat.*

1211   *Commun.* **11**, 1–6 (2020).

1212   93.   Johnson, M. C. *et al.* Optimized pseudotyping conditions for the SARS-COV2 Spike

1213   glycoprotein 2. *bioRxiv* doi:doi.org/10.1101/2020.05.28.122671

1214   94.   Aguilar, H. C., Anderson, W. F. & Cannon, P. M. Cytoplasmic tail of Moloney murine

1215   leukemia virus envelope protein influences the conformation of the extracellular domain:

1216   implications for mechanism of action of the R Peptide. *J. Virol.* **77**, 1281–91 (2003).

1217   95.   Bosch, B. J., de Haan, C. A. M., Smits, S. L. & Rottier, P. J. M. Spike protein assembly

1218   into the coronavirion: exploring the limits of its sequence requirements. *Virology* **334**,

1219   306–318 (2005).

96.   Shulla, A. & Gallagher, T. Role of Spike Protein Endodomains in Regulating Coronavirus

Entry. *J. Biol. Chem.* **284**, 32725–32734 (2009).

97. McBride, C. E. & Machamer, C. E. Palmitoylation of SARS-CoV S protein is necessary

for partitioning into detergent-resistant membranes and cell–cell fusion but not interaction

with M protein. *Virology* **405**, 139–148 (2010).

98. Lin, H.-X. *et al.* Characterization of the spike protein of human coronavirus NL63 in

receptor binding and pseudotype virus entry. *Virus Res.* **160**, 283–293 (2011).

99. Wyss, S. *et al.* Regulation of Human Immunodeficiency Virus Type 1 Envelope

Glycoprotein Fusion by a Membrane-Interactive Domain in the gp41 Cytoplasmic Tail. *J.*

Virol. **79**, 12231–12241 (2005).

100. Edwards, T. G. *et al.* Truncation of the Cytoplasmic Domain Induces Exposure of

Conserved Regions in the Ectodomain of Human Immunodeficiency Virus Type 1

Envelope Protein. *J. Virol.* **76**, 2683–2691 (2002).

101. Waning, D. L., Russell, C. J., Jardetzky, T. S. & Lamb, R. A. Activation of a

paramyxovirus fusion protein is modulated by inside-out signaling from the cytoplasmic

tail. *Proc. Natl. Acad. Sci.* **101**, 9217–9222 (2004).

102. da Silva, E., Mulinge, M. & Bercoff, D. The frantic play of the concealed HIV envelope

cytoplasmic tail. *Retrovirology* **10**, 54 (2013).

103. Aguilar, H. C. *et al.* Polybasic KKR Motif in the Cytoplasmic Tail of Nipah Virus Fusion

Protein Modulates Membrane Fusion by Inside-Out Signaling. *J. Virol.* **81**, 4520–4532

(2007).

104. Negrete, O. A. *et al.* Two Key Residues in EphrinB3 Are Critical for Its Use as an

Alternative Receptor for Nipah Virus. *PLoS Pathog.* **2**, 0078–0086 (2006).

105. Hoffmann, M. *et al.* SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is

1244   Blocked by a Clinically Proven Protease Inhibitor. *Cell* **181**, 271-280.e8 (2020).

1245   106.   Stadlbauer, D. *et al.* SARS‑CoV‑2 Seroconversion in Humans: A Detailed Protocol for a

1246   Serological Assay, Antigen Production, and Test Setup. *Curr. Protoc. Microbiol.* **57**,

1247   (2020).

1248   107.   Heurich, A. *et al.* TMPRSS2 and ADAM17 Cleave ACE2 Differentially and Only

1249   Proteolysis by TMPRSS2 Augments Entry Driven by the Severe Acute Respiratory

1250   Syndrome Coronavirus Spike Protein. *J. Virol.* **88**, 1293–1307 (2014).

1251   108.   Afar, D. E. H. *et al.* Catalytic Cleavage of the Androgen-regulated TMPRSS2 Protease

1252   Results in Its Secretion by Prostate and Prostate Cancer Epithelia. *Cancer Res.* **61**, 1686

1253   LP – 1692 (2001).

1254   109.   Joyner, M. J. *et al.* Early Safety Indicators of COVID-19 Convalescent Plasma in 5,000

1255   Patients. *medRxiv* (2020). doi:10.1101/2020.05.12.20099879

1256   110.   Muruato, A. E. *et al.* A high-throughput neutralizing antibody assay for COVID-19

1257   diagnosis and vaccine evaluation. *bioRxiv* 2020.05.21.109546 (2020).

1258   doi:10.1101/2020.05.21.109546

1259   111.   Crawford, K. H. D. *et al.* Protocol and Reagents for Pseudotyping Lentiviral Particles with

1260   SARS-CoV-2 Spike Protein for Neutralization Assays. *Viruses* **12**, 513 (2020).

1261   112.   Ritz, C., Baty, F., Streibig, J. C. & Gerhard, D. Dose-Response Analysis Using R. *PLoS*

1262   *One* **10**, e0146021 (2015).

1263   113.   Sebaugh, J. L. Guidelines for accurate EC50/IC50 estimation. *Pharm. Stat.* **10**, 128–134

1264   (2011).

1265   114.   Figar, S. *et al.* Community-level SARS-CoV-2 Seroprevalence Survey in urban slum

1266   dwellers of Buenos Aires City, Argentina: a participatory research. *medRxiv* (2020).

1267

1268

Figure 1. Production of VSVΔG-rLuc bearing SARS-CoV-2 spike glycoprotein.

Figure 2. CoV2pp entry is enhanced by trypsin treatment.

Figure 3. Trypsin-treated CoV2pp depend on ACE2 and TMPRSS2 for entry.

Figure 4. CoV2pp viral neutralization assay and absIC50/90 versus Spike binding of patient sera.

Figure 5. CoV2pp viral neutralization assay validated against patient sera by external groups.

Table 1. Comparison of ELISA endpoint titers to CoV2pp neutralization.

		IC$_{50}$ Summary [fraction of samples (%)]			IC$_{80}$ Summary [fraction of samples (%)]		
		≥ 25th percentile	≥ median	≥ 75th percentile	≥ 25th percentile	≥ median	≥ 75th percentile
Endpoint ELISA	320	7/11 (63.6%)	0/11 (0%)	0/11 (0%)	4/11 (36.4%)	1/11 (9.1%)	0/11 (0%)
	960	6/8 (75%)	4/8 (50%)	0/8 (0%)	7/8 (87.5%)	4/8 (50%)	1/8 (12.5%)
	2880	11/11 (100%)	11/11 (100%)	10/11 (90.9%)	11/11 (100%)	10/11 (90.9%)	5/11 (45.5%)

Figure 6. 293T stably transduced with ACE2 and TMPRSS2 (293T-ACE2+TMPRSS2) are ultra-permissive for SARS-CoV-2pp infection

Figure 7. Ultra-permissive 293T-ACE2+TMPRSS2 cell clones retains the same phenotypic sensitivity to convalescent COVID-19 sera.